Jasper Therapeutics
JSPR
22 hedge funds and large institutions have $15.7M invested in Jasper Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
106% more capital inflows, than outflows
Capital inflows: $1.46M | Capital outflows: $709K
0.96% more ownership
Funds ownership: 54.47% → 55.43% (+0.96%)
4% less funds holding
Funds holding: 23 → 22 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fernwood Investment Management
Quincy,
Massachusetts
|
+$544K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$334K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$236K |
| 4 |
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$156K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$578K |
| 2 |
BIT Capital
Berlin,
Germany
|
-$57.9K |
| 3 |
Two Sigma Securities
New York
|
-$32K |
| 4 |
Goldman Sachs
New York
|
-$20K |
| 5 |
Penserra Capital Management
Orinda,
California
|
-$12K |
JSPR Hedge Fund Activity: Q3 2022 in Review
22 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2022, worth a combined $15.7M — down 58% from $37.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of JSPR and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Fernwood Investment Management, opening a new position worth an estimated $544K. The largest seller was Sectoral Asset Management, cutting an estimated $578K.
- 22 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2022, down from 23 in Q2 2022.
- Funds reported $15.7M of Jasper Therapeutics stock for Q3 2022, down 58% quarter-over-quarter.
- 4 funds opened new Jasper Therapeutics positions in Q3 2022 and 5 closed out, a net change of -1 holder.
- The largest Jasper Therapeutics buyer in Q3 2022 was Fernwood Investment Management, an estimated $544K added.
- The largest Jasper Therapeutics seller in Q3 2022 was Sectoral Asset Management, an estimated $578K sold.
Based on aggregated 13F filings for Q3 2022.